Meeting
2024 ASCO Genitourinary Cancers Symposium
The Capio Prostate Cancer Center model for prostate cancer diagnostics using Stockholm3, MRI, and targeted biopsies: Real-world evidence from 2018 to 2022.
Authors
Thorgerdur Palsdottir
Karolinska Institutet, Stockholm, Sweden
Thorgerdur Palsdottir , Harold Söderbäck , Fredrik Jäderling , Martin Bergman , Hari Thambiah Vigneswaran , Henrik Gronberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 295)
DOI
10.1200/JCO.2024.42.4_suppl.295
Abstract #
295
Poster Bd #
M8
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
The impact of genomic biomarkers on a validated clinical risk prediction model for upgrading/upstaging among men with low-risk prostate cancer.
First Author: Avery Braun
Poster
2024 ASCO Genitourinary Cancers Symposium
Contemporary diagnosis of very low risk prostate cancer in a multi-centered hospital system.
First Author: Richard Bennett IV
Poster
2022 ASCO Genitourinary Cancers Symposium
Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126.
First Author: Daniel Eidelberg Spratt
Poster
2021 Genitourinary Cancers Symposium
Treatment decisions and outcomes for NCCN favorable intermediate-risk prostate cancer patients after receiving the 17-gene genomic prostate cancer score result.
First Author: Eric Margolis